| 초록 |
As long as cancer and infectious diseases exist, it is necessary to research the vaccines. However, there are hurdles of the conventional vaccines. For example, most emerging virus vaccines require rapid development and large scale production. But antibody-based treatments are hard to be implemented because of costs and manufacturing challenges inherent to protein-based therapeutics. Also, DNA vaccines have a risk of integration into the host genome. Messenger RNA (mRNA), a type of RNA, serves as a template for the production of chemically encoded proteins. mRNA vaccines have high efficacy and potential for low-cost manufacturing processes. In addition, mRNA is non-integrating and degrades naturally. Therefore, there has been growing interest in mRNA vaccine recently. Despite these advantages, obstacles make application difficult. mRNA has concerns with instability and needs to be delivered through the cell membrane. For this reasons, the development of the delivery system is urgent. |
